Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (Myeloma XI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01554852 |
Recruitment Status : Unknown
Verified June 2018 by University of Leeds.
Recruitment status was: Active, not recruiting
First Posted : March 15, 2012
Last Update Posted : June 11, 2018
|
Sponsor:
University of Leeds
Collaborators:
Celgene
Merck Sharp & Dohme LLC
Amgen
Information provided by (Responsible Party):
University of Leeds
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | December 2021 |
Estimated Study Completion Date : | December 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):